Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | ACHE | P22303 | 3/20 | 0.44 |
| ▸ | NQO2 | P16083 | 3/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29193601 | 1.00 | ESR1 (0.49) | ESR1ESR2CYP26A1MTNR1AMTNR1B | |
| SCHEMBL226397 | 0.93 | MTNR1A (0.53) | CYP26A1MTNR1AMTNR1BCA1CA2 | |
| SCHEMBL225188 | 0.86 | ESR1 (0.52) | ESR1ESR2CYP26A1MTNR1AMTNR1B | |
| SCHEMBL228890 | 0.85 | CYP26A1 (0.51) | ESR1ESR2CYP26A1MTNR1AMTNR1B | |
| SCHEMBL24452617 | 0.84 | ESR1 (0.58) | ESR1ESR2CYP26A1MTNR1AMTNR1B | |
| SCHEMBL227569 | 0.84 | MTNR1A (0.51) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL31018796 | 0.84 | ESR1 (0.58) | ESR1ESR2CYP26A1MTNR1AMTNR1B | |
| SCHEMBL227882 | 0.84 | ESR1 (0.58) | ESR1ESR2CYP26A1MTNR1AMTNR1B | |
| SCHEMBL30716420 | 0.84 | ESR1 (0.58) | ESR1ESR2CYP26A1MTNR1AMTNR1B | |
| SCHEMBL225049 | 0.83 | ESR1 (0.50) | ESR1ESR2CYP26A1MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117902990-A | Preparation method of ilalastine intermediate (R) -6- (2-amino-4-methoxyphenyl) -5,6,7, 8-tetrahydronaphthalene-2-ol | 海化生命(厦门)科技有限公司 | 2024-04-19 | — | — | CN | claimed |
| CN-122010758-A | Method for preparing key intermediate of ilalastine | 上海格苓凯生物科技有限公司 | 2026-05-12 | — | — | CN | disclosed |
| CN-122010758-A | Method for preparing key intermediate of ilalastine | 上海格苓凯生物科技有限公司 | 2026-05-12 | — | — | CN | disclosed |
| CN-117902990-A | Preparation method of ilalastine intermediate (R) -6- (2-amino-4-methoxyphenyl) -5,6,7, 8-tetrahydronaphthalene-2-ol | 海化生命(厦门)科技有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-117902990-A | Preparation method of ilalastine intermediate (R) -6- (2-amino-4-methoxyphenyl) -5,6,7, 8-tetrahydronaphthalene-2-ol | 海化生命(厦门)科技有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-20220162233-A1 | PROCESSES AND COMPOUNDS | RADIUS HEALTH, INC. | 2022-05-26 | — | — | US | disclosed |
| EP-3924328-A1 | PROCESSES AND COMPOUNDS | Radius Pharmaceuticals, Inc. (US) | 2021-12-22 | — | — | EP | disclosed |
| WO-2020167855-A1 | PROCESSES AND COMPOUNDS | RADIUS PHARMACEUTICALS, INC. (US) | 2020-08-20 | — | — | WO | disclosed |
| WO-2020167855-A1 | PROCESSES AND COMPOUNDS | RADIUS PHARMACEUTICALS, INC. (US) | 2020-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162233-A1 | PROCESSES AND COMPOUNDS | ESR1, ESR2, CYP19A1 | ESR1 1/4885ESR2 2/4885CYP26A1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.